News
Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being ...
GSK, which also has phase 3 programmes running for depemokimab in EGPA and HES, has previously put a target peak sales figure of £3 billion ($3.9 billion) a year on the drug.
GSK's long-acting drug antibody for severe asthma, depemokimab, cut the rate of attacks by 54% in phase 3 trials presented at ERS.
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.
Find the latest GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS) stock quote, history, news and other vital information to help you with your stock trading and investing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results